211 related articles for article (PubMed ID: 27691052)
1. mTOR Inhibitors for the Treatment of Severe Congenital Hyperinsulinism: Perspectives on Limited Therapeutic Success.
Szymanowski M; Estebanez MS; Padidela R; Han B; Mosinska K; Stevens A; Damaj L; Pihan-Le Bars F; Lascouts E; Reynaud R; Ferreira C; Bansept C; de Lonlay P; Saint-Martin C; Dunne MJ; Banerjee I; Arnoux JB
J Clin Endocrinol Metab; 2016 Dec; 101(12):4719-4729. PubMed ID: 27691052
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus Therapy and Follow-up in a Patient with Severe Congenital Hyperinsulinism Following Subtotal Pancreatectomy.
Chen Q; Chen Y; Wang X; Yang H; Zhang Y; Liu X; Yan Y; Wei H
J Clin Res Pediatr Endocrinol; 2021 Feb; 13(1):119-123. PubMed ID: 32482020
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia.
Senniappan S; Alexandrescu S; Tatevian N; Shah P; Arya V; Flanagan S; Ellard S; Rampling D; Ashworth M; Brown RE; Hussain K
N Engl J Med; 2014 Mar; 370(12):1131-7. PubMed ID: 24645945
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus and everolimus in kidney transplantation.
Moes DJ; Guchelaar HJ; de Fijter JW
Drug Discov Today; 2015 Oct; 20(10):1243-9. PubMed ID: 26050578
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus in infants with congenital hyperinsulinism (CHI) - a single-centre experience.
Panigrahy N; Chirla DK; Bagga N; Gunda RK; Sukhija B; Reddy L
Eur J Pediatr; 2022 Jan; 181(1):407-412. PubMed ID: 34304300
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus in the treatment of three infants with diffuse congenital hyperinsulinism.
Al-Balwi R; Al-Atawi M; Al-Otaibi A; Babiker O; Al-Mutair A
J Pediatr Endocrinol Metab; 2017 Aug; 30(9):1013-1017. PubMed ID: 28787272
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex.
Ebrahimi-Fakhari D; Agricola KD; Tudor C; Krueger D; Franz DN
Pediatr Neurol; 2020 Apr; 105():59-61. PubMed ID: 31924480
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sirolimus in a neonate with persistent hypoglycaemia following near-total pancreatectomy for hyperinsulinaemic hypoglycaemia.
Abraham MB; Shetty VB; Price G; Smith N; Bock Md; Siafarikas A; Resnick S; Whan E; Ellard S; Flanagan SE; Davis EA; Jones TW; Hussain K; Choong CS
J Pediatr Endocrinol Metab; 2015 Nov; 28(11-12):1391-8. PubMed ID: 26226122
[TBL] [Abstract][Full Text] [Related]
9. Safety of mTOR inhibitors in adult solid organ transplantation.
Ventura-Aguiar P; Campistol JM; Diekmann F
Expert Opin Drug Saf; 2016; 15(3):303-19. PubMed ID: 26667069
[TBL] [Abstract][Full Text] [Related]
10. Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience.
Krueger DA; Capal JK; Curatolo P; Devinsky O; Ess K; Tzadok M; Koenig MK; Narayanan V; Ramos F; Jozwiak S; de Vries P; Jansen AC; Wong M; Mowat D; Lawson J; Bruns S; Franz DN;
Eur J Paediatr Neurol; 2018 Nov; 22(6):1066-1073. PubMed ID: 30005812
[TBL] [Abstract][Full Text] [Related]
11. Extreme caution on the use of sirolimus for the congenital hyperinsulinism in infancy patient.
Banerjee I; De Leon D; Dunne MJ
Orphanet J Rare Dis; 2017 Apr; 12(1):70. PubMed ID: 28410602
[TBL] [Abstract][Full Text] [Related]
12. High Incidence of Ovarian Cysts in Women Receiving mTOR Inhibitors After Renal Transplantation.
Bachmann F; Glander P; Budde K; Bachmann C
J Womens Health (Larchmt); 2018 Mar; 27(3):394-398. PubMed ID: 29087803
[TBL] [Abstract][Full Text] [Related]
13. [Extra-renal adverse effects of mTOR inhibitors: know them to optimize their use in renal transplantation].
Caletti C; Granata S; Tomei P; Lupo A; Zaza G
G Ital Nefrol; 2014; 31(4):. PubMed ID: 25098457
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
Fernandes-Silva G; Ivani de Paula M; Rangel ÉB
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
[TBL] [Abstract][Full Text] [Related]
15. Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures.
Yang MT; Lin YC; Ho WH; Liu CL; Lee WT
J Neuroinflammation; 2017 Jan; 14(1):15. PubMed ID: 28109197
[TBL] [Abstract][Full Text] [Related]
16. mTOR and Cardiovascular Diseases: Diabetes Mellitus.
Vergès B
Transplantation; 2018 Feb; 102(2S Suppl 1):S47-S49. PubMed ID: 28263222
[TBL] [Abstract][Full Text] [Related]
17. The Effectiveness of Sirolimus Treatment in Two Rare Disorders with Nonketotic Hypoinsulinemic Hypoglycemia: The Role of mTOR Pathway.
Şıklar Z; Çetin T; Çakar N; Berberoğlu M
J Clin Res Pediatr Endocrinol; 2020 Nov; 12(4):439-443. PubMed ID: 32157856
[TBL] [Abstract][Full Text] [Related]
18. Morphoproteomics and biomedical analytics coincide with clinical outcomes in supporting a constant but variable role for the mTOR pathway in the biology of congenital hyperinsulinism of infancy.
Brown RE; Senniappan S; Hussain K; McGuire MF
Orphanet J Rare Dis; 2017 Dec; 12(1):181. PubMed ID: 29246172
[TBL] [Abstract][Full Text] [Related]
19. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.
Molas-Ferrer G; Soy-Muner D; Anglada-Martínez H; Riu-Viladoms G; Estefanell-Tejero A; Ribas-Sala J
Nefrologia; 2013; 33(3):297-300. PubMed ID: 23712219
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and phenotype-genotype review of 25 Omani children with congenital hyperinsulinism in infancy. A one-decade single-center experience.
Al-Badi MK; Al-Azkawi HS; Al-Yahyaei MS; Mula-Abed WA; Al-Senani AM
Saudi Med J; 2019 Jul; 40(7):669-674. PubMed ID: 31287126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
